Objectives: Evaluation of nephrotoxicity of a novel amphotericin B (AMB) formulation with dioctadecyldimethylammonium bromide (DODAB) bilayer fragments (DOD/AMB).
Introduction
A limited spectrum of antimycotic agents is available for the treatment of disseminated fungal infections. Amphotericin B (AMB) is the therapy of choice for most invasive Candida infections. [1] [2] [3] This broad-spectrum fungicide is a polyene antibiotic that exerts its toxic effect on fungal cells by forming complexes with membrane sterols 4, 5 that can act as transmembrane channels, allowing leakage of ions and other vital components from the cell. 6 Unfortunately, AMB nephrotoxicity is high 1, 2, 4 and has often been related to the occurrence of AMB as large aggregates both in water solution and in the lipid membrane. 7, 8 The low AMB solubility in water and in many organic solvents is a problem that is not easily solved. In order to formulate AMB, liposomes, 9 surfactants, 10 oil-in-water emulsions 11, 12 and cochleates 13, 14 have been used, and have certainly improved the therapeutic index of the drug. However, Fungizone (DOC/AMB), the very first formulation for the drug using the bile salt desoxycholate (DOC), is still the most frequently used formulation in clinics despite the formation of a very unstable and toxic detergent -micelle complex. 8, 15, 16 The reason for this seems to be related to two major drawbacks of lipid-based formulations:
(i) AMB is required at higher doses than those in DOC/AMB (owing to competition between carrier lipids and fungus membrane for drug solubilization); 8, 17 and (ii) lipids in the formulations are expensive. 15 Dioctadecyldimethylammonium bromide (DODAB) is a synthetic and inexpensive cationic lipid that assembles in water solution forming bilayer vesicles 18 or bilayer fragments 19 depending on the dispersion method. DODAB bilayer vesicles have been used as interface agents in several instances 20 such as vaccine adjuvants interacting with different antigens, 21 -25 biocidal agents against bacteria 26 -29 and fungi, 17 and they exhibit differential cytotoxicity. 30 -32 Solubilization of AMB by nanosized, synthetic and charged bilayer fragments electrostatically stabilized in water dispersion has been described; unlike other formulations this did not make use of entire and closed bilayer vesicles. 33 These results were also extended to include miconazole, a clinically important hydrophobic drug, which was solubilized and/or colloidally stabilized using synthetic bilayer fragments. 34 The AMB solubilization was explained by the very large area of hydrophobic nanosurfaces offered by the bilayer fragments, so that the polyenic moiety of the antibiotic interacted with the hydrophobic borders of the bilayer fragments, while the hydroxylated moiety of the drug remained in contact with the surrounding water from its solubilization site 32 -34 ( Figure 1 ). Recently, the DODAB bilayer fragment/AMB formulation, DOD/AMB, was compared with the classical deoxycholate AMB formulation, DOC/AMB, in vivo against a mouse model of systemic candidiasis. 35 The drug was present in the DOD/AMB formulation mostly in its monomeric form, as indicated by the UV-visible absorption spectra and dynamic light scattering particle sizing. 35 Survival and tissue burden experiments showed that a relatively low dose of AMB (0.4 mg/kg/day given intraperitoneally for 10 consecutive days) in the form of DOD/AMB was as efficient as the same dose in DOC/AMB against systemic candidiasis. In comparison with other lipid formulations, the main advantage of the inexpensive DOD/AMB formulation is a high efficiency at a low AMB dose. However, the nephrotoxicity of this novel formulation required further evaluation, since this is a central issue to be solved when AMB is used in therapy. 36 -38 In this work, the dose-dependent toxicity of DOD/AMB was evaluated in vitro against cultured kidney epithelial cells, and was lower than that of DOC/AMB. In vivo, nephrotoxicity was evaluated from renal function parameters and histopathology of renal cortex, and was also lower for DOD/AMB than for DOC/AMB. 
Materials and methods

Drug
Preparation of DOD/AMB formulation
The DODAB synthetic bilayer fragments were obtained by sonication with a titanium macrotip probe. 18 The method for obtaining large and closed DODAB vesicles was previously described in 1983, 18 and consisted of injecting a chloroformic DODAB solution in a water solution kept at 708C (above chloroform boiling point and above the mean phase transition temperature for the DODAB bilayer). The method for obtaining open DODAB bilayer fragments based on sonication with a tip was also previously described 18 and discussed in comparison to others. 19 The final DODAB concentration was determined by microtitration 39 and adjusted to 10 g/L. AMB solubilization in the 10 g/L DODAB synthetic bilayer fragments dispersion was performed in the absence of any organic solvent, and the final AMB concentration was 0.05 g/L (DOD/AMB formulation). At final concentrations of AMB < _ 0.1 g/L (10 g/L DODAB), no AMB yellow aggregates could be detected in the pellet of centrifuged samples. As a control for complete AMB solubilization in the DODAB synthetic bilayer fragments, increasing concentrations of AMB and 10 g/L DODAB synthetic bilayer fragments were mixed, incubated (258C, 24 h) and centrifuged (15 000 g for 50 min). No yellow pellet was observed for AMB concentrations < 0.1 g/L; all AMB molecules were solubilized at the hydrophobic rim of the DODAB bilayer fragments, 33 whereas the control mixtures (without DODAB) displayed yellow pellets at the bottom of the glass assay tubes. The bilayer fragments, as usual, remained in the supernatant. DOC/AMB was diluted in 5% glucose for parenteral administration, as recommended. Determination of in vitro activity of DODAB against C. albicans C. albicans ATCC 90028 and HU168 strains were subcultured on Sabouraud dextrose agar (SDA) plates and grown at 358C for 24 h prior to testing. The macrodilution method was performed according to the recommendations of the NCCLS. 41 The medium used for diluting cells was 0.264 M D-glucose. The interaction between DODAB and components of the culture medium would completely prevent targeting of the cationic DODAB -drug complex to the oppositely charged Candida cells. 17 Counts for cell suspension were confirmed by plating on SDA plates after adjusting to 2.5 Â 10 3 cfu/mL. C. albicans viability in the presence of DODAB formulations was determined by cfu counts in a volume of 0.1 mL after 48 h of incubation at 358C. 42 
Culture of kidney epithelial cells (Vero cells from African green monkey)
The kidney epithelial cells were grown as a subconfluent monolayer in 250 mL flasks containing complete minimum essential medium (MEM), 20 mM glutamine and 1% non-essential amino acids, supplemented with 10% bovine fetal serum, penicillin (100 IU/mL) and streptomycin (100 g/L) under a humidified atmosphere containing 5% CO 2 at 378C. Before harvesting and plating cells for the experiments, cells were treated with trypsin and cell concentration (cells/mL) was determined using a Neubauer chamber.
Determination of in vitro cytotoxicity against cultured kidney epithelial cells
The in vitro cytotoxicity against kidney epithelial cells was evaluated by means of a Neutral Red uptake assay. 43, 44 Neutral Red is a vital dye that is endocytosed by viable cells and internalized inside lysosomes; in this respect it is considered an indicator of lysosome (and cell) integrity. 43, 44 Cells (1 Â 10 5 ) in 0.2 mL of culture medium were plated per microplate well. Twenty-four hours after cell seeding, the medium was aspirated from the monolayer and replaced with 0.2 mL of AMB formulation over a range of AMB and DODAB concentrations (0.3-20 g/L and 0.06-4.0 g/L, respectively). Two controls for 0 or 100% viability were performed by incubating cells in 0.1% (w/v) Triton X-100 or in culture medium only, respectively. Samples and controls were tested in triplicate, and two independent experiments were carried out. The plates were incubated for 1 h at 378C in a humidified 5% CO 2 incubator. Thereafter, the medium was aspirated from the monolayer, the cell layer was washed twice with phosphate-buffered saline (PBS) pH 7.4, and the medium was replaced by 0.1 mL of MEM containing 6.7 mg of Neutral Red dye. After 2 h of incubation at 378C, the dye-containing medium was discarded, the wells were washed twice with PBS pH 7.4 and the dye incorporated by the cells was extracted with 0.1 mL of an extractant solution (50% ethanol in acetic acid, 1%). Microplates were shaken gently on a microplate rotator for 2 min before determining absorbance at 540 nm by means of a microplate reader (Ultramark, Model 550; Bio-Rad, Hercules, CA, USA). Percentage viability was calculated by (A 540 treated cells /A 540 untreated cells )Â100 and expressed as mean ± S.D. Percentage cytotoxicity was calculated from: 100Àpercentage viability.
Determination of in vivo toxicity after repeated administration
Toxicity was evaluated from percentage average weight change, relative spleen weights, determination of hepatic and renal function by biochemical parameters, and renal histopathology. Measurements were performed for 4 groups of 10 female mice (for histopathology and other evaluations) and 4 groups of 15 female mice (for blood parameters). Two groups received DOD/AMB (DODAB/AMB, 80:0.4 mg/kg/day); two groups received DOC/AMB (AMB 0.4 mg/kg/day); two groups received DODAB (80 mg/kg/day); and two control groups received sterile dextrose, 5% in water. For 10 days, 240 mL of each formulation was given daily by intraperitoneal injection. The protocol choice was based on the survival evaluation of in vivo activity of the formulation against systemic candidiasis in a mouse model. 
Determination of hepatic and renal function
At day 11 after injection, five mice from each group were weighed and euthanized. Blood was collected without anticoagulant, centrifuged at 2000 g and the serum was frozen at À308C until analysis. For each experimental condition, serum pools were prepared by mixing equal volumes collected from three mice so that five serum pools were obtained. Alkaline phosphatase (ALP) activity, transaminase activity, and serum urea and creatinine levels were determined in 1 mL of each serum pool using an auto-analyser for clinical chemistry assay (LIASYS Random Access Analyzer; AMS, Roma, Zenica). The auto-analyser was validated for mouse liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST) and ALP] before analytical determinations.
Histopathology of renal cortex
At day 11 and 180 after injection, five mice from each group were weighed and euthanized. The kidneys were carefully dissected and fixed by immersion in a 10% solution of buffered formalin (pH 7.4). Transverse sections were processed according to usual histological techniques for paraffin embedding. Five micrometre sections were taken and stained with haematoxylin and eosin.
Statistical analysis
All data are expressed as means ± S.D. Differences between groups were analysed by ANOVA one-way multiple comparison tests, and the Kruskal-Wallis non-parametric test was used when needed. A P value of < _ 0.05 was considered significant.
Results and discussion
DODAB, DOD/AMB and DOC/AMB cytotoxicity in vitro
The DOD/AMB formulation based on a single synthetic lipid which forms bilayer fragments upon sonication with a tip is shown schematically in Figure 1 . Bilayer fragments are bilayer discs produced by ultrasonically dispersing certain synthetic lipids in water solution. They have been observed by transmission electron microscopy (TEM) 45 and cryo-TEM 46 over the last 20 years for single lipid dispersions, such as those of sodium dihexadecylphosphate, or dioctadecyldimethylammonium bromide or chloride. DODAB bilayer fragments 33 are stiff and flat due to their rigid gel state at room temperature. 47 They are composed of open, charged and electrostatically stabilized bilayer pieces obtained from sonication with a tip. This is a high energy input procedure that not only disperses the lipid powder in water producing bilayer vesicles, but also disrupts them, thereby originating bilayer fragments. The main pieces of evidence for their existence are: (i) osmotic non-responsiveness of the dispersion indicative of absence of inner vesicle compartment; (ii) TEM micrographs with electronic staining; 45 (iii) cryo-TEM micrographs; 46 (iv) quasielastic light scattering and electron paramagnetic resonance spectroscopy; and (v) solubilization of hydrophobic drugs such as AMB at the borders of DODAB bilayer fragments, which does not occur for DODAB closed bilayer vesicles. 19, 33, 45, 46 They differ from the closed vesicles in the AmBisome formulation by providing hydrophobic borders at their edges that are absent in closed bilayer systems such as vesicles or liposomes. The inexpensive DODAB synthetic lipid is a potent bactericide 26 -28,32 and exhibits cytotoxicity against mammalian cells in culture 30, 32 that is much lower than against prokaryotic or yeast cells. 17, 32 Bacteria are very susceptible to DODAB, with micromolar DODAB concentrations effectively killing four bacteria species of clinical importance. Table 1 shows DODAB concentrations for 0% survival of C. albicans HU168 and C. albicans ATCC 90028: 0.8 and 0.4 mM, respectively. Therefore, DODAB concentrations for killing yeast cells are much higher than those required to kill bacteria. Regarding kidney epithelial cells, the DODAB concentration required for 50% survival of cultured cells was 5.4 mM, i.e. these cells were much less susceptible to DODAB than bacteria or yeast cells.
Percentage cytotoxicity against kidney epithelial cells as a function of DODAB and AMB concentrations is shown in Figure 2 . Two AMB formulations were tested: (i) DOD/AMB based on DODAB lipid only; and (ii) DOC/AMB based on deoxycholate. At equivalent AMB doses, DOC/AMB cytotoxicity against cultured kidney epithelial cells was higher than DOD/AMB over a range of AMB concentrations (Figure 2a) . It was interesting to note that despite DODAB cytotoxicity (Figure  2b) , the DOD/AMB formulation was less toxic than DOC/AMB. Schematically illustrated in Figure 1 , the monomeric form of AMB in the DOD/AMB formulation 33 was less toxic against kidney cells than drug aggregates that are extensively present in DOC/AMB. 7, 8 This is in agreement with previous results showing that the aggregated form of AMB is more toxic against human erythrocytes and other cultured mammalian cells than the monomeric form of the drug. 48 
DODAB, DOD/AMB and DOC/AMB toxicity in vivo
At day 11 after injection of each formulation in mice, DODAB, DOD/AMB and DOC/AMB did not affect any of the serum biochemical parameters currently used to evaluate renal and hepatic function ( Table 2) . Activity of ALT, AST or ALP, as well as creatinine and urea concentrations in serum, were not altered relative to controls after intraperitoneal administration of 80 mg/kg/day DODAB or 80/0.4 mg/kg/day DOD/AMB or 0.4 mg/kg/day AMB in DOC/AMB for 10 consecutive days. In clinics, DOC/AMB is used at doses < _ 1.0 mg/kg/day 1-3 because this is the limit for tolerable nephrotoxicity, meaning no significant changes in creatinine serum level. Above this limit, nephrotoxicity and creatinine serum levels rapidly increase within days of treatment. One should note that the present study was conducted at low AMB doses both for DOC/AMB and DOD/AMB owing to the high efficacy of the DOD/AMB formulation. 35 Therefore, increases in creatinine serum levels were not expected even for DOC/AMB. In fact, measured creatinine levels did not increase at day 11 compared with controls for both formulations ( Table 2) . As a more sensitive marker for nephrotoxicity, renal histopathology examination revealed differences between DOC/ AMB and DOD/AMB effects on renal morphology.
In comparison with the usual AMB dose for liposomal AMB, AmBisome, which is 3 mg/kg/day for 10 consecutive days, 38, 49 the DOD/AMB monomeric formulation contained $ 10 times less drug and even so yielded high efficacy of treatment in model mice where candidiasis had been developed. 35 Thus, this low dose as employed in this work was previously reported to yield 100% mice survival, among several efficacy parameters. 35 Essentially, survival had been defined as one of the primary efficacy variables in the quoted study.
35
DODAB and DOD/AMB formulations reduced the percentage average weight change, whereas DOC/AMB did not (Figure 3) . Nevertheless, this effect was reversible and not significant over the long term (see percentage average weight at day 180 in Table 2 . Effect of DODAB, DOD/AMB and DOC/AMB on serum biochemical data at day 11 after injection of each formulation DOD/AMB and DOC/AMB were used at therapeutic doses (DODAB and AMB doses at 80 and 0.4 mg/kg/day, respectively) for 10 consecutive days. Data are presented as means ± S.D. (n = 5 serum pools for each group). . DODAB has been recognized as an efficient immunostimulator in animals. 21 -24 On the other hand, the normal pathway of drug clearance from the peritoneum is through direct absorption across the peritoneal membrane and by drainage into the lymphatic system. 50 Owing to intraperitoneal administration, the formulations were expected to interact with the spleen, the main lymphatic organ connected to systemic circulation. DODAB, DOD/AMB and DOC/AMB affected relative spleen weight as a percentage of body weight as determined at days 11 and 180 after administration. The spleen responded to DODAB formulations by having significantly increased relative weight at day 11 (Table 3) . However, this effect receded at day 180, at which point no significant increase in relative spleen weight was seen (Table 3 ). In contrast, DOC/AMB, which was not expected to act as an immunostimulator, did not affect relative spleen weight.
When injected subcutaneously as adjuvant to present a variety of antigens, DODAB has been reported to form local depots that lasted up to 60 days in mice, without any evidence of overt toxicity. 22, 23 In fact, autopsy of euthanized animals in this work revealed an intraperitoneal depot at day 11 that was identified by histopathological examination as chronic necrotizing (N. Lincopan, P. Borelli, R. A. Fock, E. M. Mamizuka and A. M. Carmona-Ribeiro, unpublished results). This lesion receded substantially by day 180.
The histopathology of the mouse kidneys at day 11 is shown in Figure 4 at two magnifications: Â100 and Â400. On the left in Figure 4 , the control showed cross-sections of intact glomeruli and normal tubuli. In the middle, DOD/AMB treatment caused mild tubular hydropic degeneration, although at Â100 magnification, the overall aspect of glomeruli and tubuli appeared normal. On the right, DOC/AMB caused early focal lymphocytic infiltrates (indicated by an asterisk) and tubular cystic degeneration filled with haemorrhagic fluid (indicated by an arrow) plus cellular debris in the lumen (indicated by 'D').
The histopathology of the mouse kidneys at day 180 is shown in Figure 5 at two magnifications: Â100 and Â400. On the left in Figure 5 , DODAB caused perivascular mononuclear infiltrate (indicated by an asterisk) and mild hydropic degeneration. In the middle, DOD/AMB showed a similar picture, also presenting mononuclear infiltrates and mild hydropic degeneration. On the right, DOC/AMB caused much more severe lesions such as irreversible damage in kidney tissues as seen from dense projections of lymphocytic infiltrates (indicated by an asterisk), focal glomerulosclerosis (indicated by 'G'), hyaline cylinders (indicated by 'H') and hyaline mass in sclerotic areas, suggesting protein reabsorption. In the literature, persistent acute tubular toxicity after switch from conventional AMB to liposomal AMB, despite complete preservation of glomeruli, has been previously reported. 51 Tubular cell function was shown to be more sensitive to high doses of liposomal AMB than glomerular cell function. 51 For the DOD/AMB formulation in comparison with AmBisome, tubular integrity remained almost unaffected (Figures 4 and 5) . It should be noted that perivascular mononuclear infiltrate could be identified from migration of mononuclear blood cells from blood vessels to the surrounding tissue in association with an inflammatory response possibly elicited by DODAB, DOD/AMB or DOC/AMB excretion via renal tubules. Hydropic degeneration, meaning water accumulation in cells with appearance of small vacuoles in the cytoplasm and cell swelling, was also observed for the three treatments. These two abnormalities were, however, milder than the severe tubular cystic degeneration with appearance of cellular debris inside the tubular lumen described for DOC/AMB only.
In summary, this toxicity study comparing DOD/AMB with conventional AMB has shown that DOD/AMB is less nephrotoxic than DOC/AMB both in vitro and in vivo. In clinical trials, early nephrotoxicity is usually controlled by monitoring creatinine levels and tubular abnormalities. In the present study, neither DOD/AMB nor DOC/AMB given at the relatively low dose of 0.4 mg/kg/day AMB, gave rise to any change in serum creatinine, and only DOC/AMB gave rise to abnormal tubuli and glomeruli upon histopathological examination. Nephrotoxicity is usually reduced with all known lipid formulations, but the use of such expensive agents should be highly restricted to those who are intolerant of or refractory to DOC/AMB. 3, 52 The main disadvantage of the DOD/AMB formulation is related to its limited capacity to carry the monomeric form of the drug: 10 g/L DODAB dispersion was able to solubilize AMB over a drug concentration range that had to be < 0.1 g/L. Therefore, the DOD/AMB treatment regimen would possibly have to be prolonged to administer small daily AMB doses distributed over a large number of days. Interestingly, the inherent immunostimulatory effect associated with DODAB carrier could be favourable to neutropenic patients, who suffer severe fungal infections. Consistently, we have been determining a DODAB-induced rise in the count of polymorphonuclear neutrophils cells in peripheral blood (N. Lincopan, P. Borelli, R. A. Fock, E. M. Mamizuka and A. M. Carmona-Ribeiro, unpublished results).
